TQ05105 (novel JAK inhibitor for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-02 — A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis: cross-connection with tq05105-jak2-inhibitor: Possible duplicate pages for the same compound (TQ05105) — consider consolidating. (novelty: 3)
- 2026-04-24 — A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis: Phase II open-label, single-arm, multi-center trial evaluating efficacy, safety, and pharmacokinetics of TQ05105 tablets in intermediate/high-risk MF patients refractory, relapsed, or intolerant to prior JAK inhibitor therapy (trial-early; results pending). (novelty: 3)
Open questions
Related
Contributing findings
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
24-apr-2026
novelty 3
per-area 3
introduces